Japer Therapeutics Warrants
JSPRW
10 hedge funds and large institutions have $345K invested in Japer Therapeutics Warrants in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
3.17% less ownership
Funds ownership: 5.34% → 2.17% (-3.2%)
20% less capital invested
Capital invested by funds: $431K → $345K (-$86.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
+$28.5K |
| 2 |
CAC
Cowen and Company
New York
|
+$18.7K |
| 3 |
Walleye Capital
New York
|
+$7.07K |
| 4 |
Morgan Stanley
New York
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
-$1.74K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAC
1
Cowen and Company
New York
| $110K | +$18.7K | +121,325 | +18% |
|
|
2
Walleye Capital
New York
| $98.2K | +$7.07K | +45,903 | +7% |
|
|
ICM
3
Ionic Capital Management
New York
| $62.2K | +$28.5K | +185,268 | +72% |
|
|
TCM
4
Tenor Capital Management
New York
| $35K | – | – | – |
|
|
HCM
5
Highbridge Capital Management
New York
| $12.8K | – | – | – |
|
|
CL
6
CSS LLC
Chicago,
Illinois
| $11.5K | – | – | – |
|
|
ZA
7
Zazove Associates
Incline Village,
Nevada
| $9K | – | – | – |
|
|
EPM
8
Equitec Proprietary Markets
Chicago,
Illinois
| $4.13K | -$1.74K | -11,270 | -25% |
|
9
Walleye Trading
New York
| $1.98K | – | – | – |
|
|
10
Morgan Stanley
New York
| $12 | +$15 | +100 | New |
|
11
Osaic Holdings
Scottsdale,
Arizona
| $5 | – | – | – |
|
JSPRW Hedge Fund Activity: Q2 2023 in Review
10 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Japer Therapeutics Warrants (JSPRW) for Q2 2023, worth a combined $345K — down 20% from $431K a quarter earlier.
Fund positioning in JSPRW was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Ionic Capital Management, adding an estimated $28.5K. The largest seller was Equitec Proprietary Markets, cutting an estimated $1.74K.
- 10 institutional investors held Japer Therapeutics Warrants (JSPRW) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $345K of Japer Therapeutics Warrants stock for Q2 2023, down 20% quarter-over-quarter.
- 1 fund opened new Japer Therapeutics Warrants positions in Q2 2023 and 1 closed out, a net change of 0 holders.
- The largest Japer Therapeutics Warrants buyer in Q2 2023 was Ionic Capital Management, an estimated $28.5K added.
- The largest Japer Therapeutics Warrants seller in Q2 2023 was Equitec Proprietary Markets, an estimated $1.74K sold.
Based on aggregated 13F filings for Q2 2023.